Continuing Besifovir Dipivoxil Maleate Versus Switching from Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B: Results of 192-Week Phase 3 Trial.

Conclusions: BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (Date: September 10, 2013). PMID: 33493393 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33493393?dopt=Abstract

Source: Clinical and molecular hepatology - January 27, 2021 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research